Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations

NCT04096417 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

14

Enrollment

OTHER

Sponsor class

Conditions

FGFR1 Gene Amplification
FGFR1 Gene Mutation
FGFR1 Gene Translocation
FGFR2 Gene Amplification
FGFR2 Gene Mutation
FGFR2 Gene Translocation
FGFR3 Gene Amplification
FGFR3 Gene Mutation
FGFR3 Gene Translocation
Metastatic Colorectal Carcinoma
Stage III Colorectal Cancer AJCC v8
Stage IIIA Colorectal Cancer AJCC v8
Stage IIIB Colorectal Cancer AJCC v8
Stage IIIC Colorectal Cancer AJCC v8
Stage IV Colorectal Cancer AJCC v8
Stage IVA Colorectal Cancer AJCC v8
Stage IVB Colorectal Cancer AJCC v8
Stage IVC Colorectal Cancer AJCC v8
Unresectable Colorectal Carcinoma

Interventions

DRUG: Pemigatinib
OTHER: Quality-of-Life Assessment

Sponsor

Academic and Community Cancer Research United

Collaborators

[object Object]